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ABSTRACT 
Solid Lipid Nanoparticles (SLN) is rapidly developing field of nanotechnology with several potential application in drug delivery and 
research. Drugs having low aqueous solubility not only possess low oral bioavailability but also exhibit high inter- and intra-subject 
variability. The purpose of the present investigation was to study bioavailability enhancement of Prazosin Hydrochloride by formulating it 
into solid lipid nanoparticle. Prazosin Hydrochloride is an antihypertensive agent with limited bioavailability as a result of low aqueous 
solubility, hence, solid lipid nanoparticle is one of the approaches to improve the bioavailability. SLN were prepared using hot 
homogenization followed by solvent emulsification-ultrasonication method. Prazosin Hydrochloride loaded SLN were optimized and 
characterized by particle size, zeta potential, XRD and DSC. Prazosin Hydrochloride loaded SLN exhibited the particle size 263.8±1.88 and 
entrapment efficiency 89.29±0.65% showed better bioavailability and optimum stability.  
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INTRODUCTION 
Oral bioavailability  depends  upon  several factors such as 
aqueous solubility, drug permeability, dissolution rate, first 
pass metabolism, pre-systematic metabolism and 
susceptibility to efflux  mechanism.1  SLN possesses 
advantages over other colloidal delivery system is to 
increase physical  stability,  high  drug  upload  and  
absence  of  carrier biotoxicity. 
The  solid  lipids  were used  in the  preparation of SLN 
instead of  liquid lipids to overcome  the  disadvantages  
associated  with  the  liquid  state and  to  improve physical  
stability. The successful application of nanoparticles for 
drug delivery depends on their ability to penetrate through 
several anatomical barriers, sustained release of their 
constants and their stability in nanometer size.  For  in-vivo  
performance the solubility and dissolution rate are very 
important  parameters.2  About 40%  of  new chemical 
entities discovered  and  many  existing  drugs  are  poorly  
soluble compounds  that leads to poor  in-vivo 
bioavailability  and  lack of  dose proportionality.  Nano 
sized drug carriers,  especially  solid  lipid  nanoparticle can  
be  the  primary approach  developed  for improvement of 
bioavailability, due  to  their  ability  to  enhance  the  
lymphatic  transport  of  the  lipophilic  drugs.3 
Hypertension is the common cardiovascular diseases.  In 
the world, about 20-50% of deaths are due to 
cardiovascular diseases. Prazosin Hydrochloride is an 
alpha blocker antihypertensive BCS class II drug.  It is used 
for the treatment of heart failure and hypertension having 
low bioavailability.4 
Active pharmaceutical ingredients with poor water 
solubility are often associated with number of in- vivo 
problems. Despite of drawbacks,  advances   have  been  
made  in   delivery  technologies  to  improve  the 
bioavailability  of  poorly  water  soluble  compounds.  
Development  of  new  drug  is  not sufficient  to  ensure 
progress  in  drug  therapy. Such  advances   in   delivery   
technologies exploited by formulation  scientist for  
bioavailability  enhancement  include  suitable  drug  
carrier  system such as microemulsion, nanoemulsion, 
liposomes, self-emulsifying delivery, solid  dispersion and 
solid  lipid  nanoparticles.5,6,7 
MATERIALS AND METHOD: 
Materials: 
Prazosin Hydrochloride was purchased from Swapnroop 
Drugs and Pharmaceuticals, Aurangabad, India, Polaxamer 
407 from Research lab fine chem. Industries, Mumbai, 
India; Glyceryl mono stearate from Hilab chemicals, 
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shrirampur, India and methanol from Molychem, Mumbai, 
India. All other chemicals used were of analytical grade. 
Method: 
Preparation of Prazosin Hydrochloride loaded Solid 
Lipid Nanoparticles: 
Prazosin Hydrochloride loaded SLNs were prepared by 
high pressure homogenization followed by solvent 
emulsification-Ultrasonication. Glyceryl monostearate 
(GMS) was dissolved in methanol by heating at 70-800C 
and 10 mg of Prazosin Hydrochloride was dissolved by 
adding into this solution.  In another beaker, aqueous 
phase was made by adding 30 ml of distilled water 
containing 30 mg of polaxamer 407 (P 407)  and heated at 
the same temperature as lipid phase Then lipid phase was 
added drop wise into aqueous phase by using magnetic 
stirrer at 1500 rpm and kept it for 2 hours. The resultant 
dispersion was immediately sonicated using a probe 
sonicator (Remi R-8C) at amplitude of 50% with the pulse 
of 4 sec intervals. Then high pressure homogenization 
(HPH) of this solution is carried out by applying 1000 bar 
pressure using 3-5 cycle.  The prepared SLNs samples were 
lyophilized at -520C for 24 hours to yield dry powder. 
Various formulations (A to H) were prepared using 
different compositions of lipid (GMS) and polymer (P407) 
(Table 1).8,9 
 
Table 1: Experimental design for preparation of solid lipid nanoparticles 
Formulation 
Drug  
(mg) 
Water 
(ml) 
Formulation composition 
Lipid polymer 
A 10 40 70 20 
B 10 40 70 30 
C 10 40 90 30 
D 10 40 90 20 
E 10 40 50 25 
F 10 40 60 15 
G 10 40 30 10 
H 10 40 60 25 
 
Characterization of Solid Lipid Nanoparticles: 
Determination of Practical yield and Entrapment 
efficiency  
The practical yield (PL) and entrapment efficiency (EE) of 
the prepared SLNs for Prazosin Hydrochloride was 
evaluated by taking 5 ml of the resultant dispersion, and 
then centrifuged at 12000 rpm for 120 min at 40C by using 
cooling centrifuge (Remi C-24BL). The clear supernatant 
layer was decanted and the remaining part was dissolved 
in 10 ml methanol, sonicated for 5 min then sample was 
filtered through filter paper no. 41 and analyzed using UV 
Visible spectrophotometer (Agilent Cary 60) at lambda 
max 248 nm. The percentage EE was calculated using 
following relationship.10 
 
Practical yield was calculated as drug analyzed in the 
nanoparticle versus the total amount of product obtained 
and total solid used in the preparation (Table 1). 
Particle Size Analysis of Nanoparticles: 
Determination of mean average particle size of Prazosin 
Hydrochloride nanoparticle was carried out by using 
Horiba scientific instrument. The analysis was performed 
by introducing 0.3 ml of sample into the viewing unit the 
dynamic light scattering is used to measure particle size 
and molecule size. The particle size analysis was 
performed at a scattering angle of 900C at room 
temperature. The diameter was averaged from three 
parallel measurements moving under Brownian motion, 
and converts this to size and a size distribution.11 
Zeta potential Measurement: 
The analysis was performed by using the Horiba scientific 
analyzer zetasizer. The electrophoretic mobility was 
converted to the zeta potential. To determine the zeta 
potential, nanoparticle sample were diluted with KCL (0.1 
mM) and placed in electrophoretic cell where an electrical 
field of 15.2V/cm was applied. All measurement was 
performed triplicate. The unique disposable capillary cell 
ensure there is no cross contamination between samples, 
which improves the simplicity, speed and accuracy of the 
measurement.11 
Scanning Electron Microscopy (SEM): 
Nanoparticles were coated with a thin gold-palladium 
layer by sputter coater unit (VG Microtech, United 
Kingdom), and the surface topography was analyzed with a 
Cambridge Stereoscan S 120 scanning electron microscope 
(SEM: Cambridge, United Kingdom) operated at an 
acceleration voltage of 10 kv.12 
Fourier Transform Infrared Spectroscopy: 
The FTIR spectra are used to identify the drug as well as to 
detect the interaction of drug with polymers. FTIR 
spectrum of pure drug and optimized batch of solid lipid 
nanoparticles was taken. Sample of solid lipid 
nanoparticles was kept onto sample holding surface for 
analysis. The spectrum was scanned over the wave number 
range 4000-400 cm-1.13 
X-Ray Diffraction Analysis: 
X-ray powder diffraction of pure drug and optimized batch 
of nanoparticles were analysed by Philips PW X-ray 
diffractometer. Sample were irradiated with 
monochromatized Cu Kα-radiation (1.542A0) and analysed. 
The voltage and current used were 30k V and 30Ma 
respectively. The range was 5 ×103 cycle/s and chart 
speed was kept at 100 mm.14 
Differential Scanning Calorimeter Analysis: 
Thermal properties of pure drug and optimized batch of 
nanoparticle were analyzed by DSC (TA Instruments, USA 
Model: SDT2960). Indium was used to calibrate the DSC 
temperature and enthalpy scale. Nitrogen was used as the 
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pure gas through DSC cell at flow rate of 50 ml per min. 
through the cooling unit. The sample was heated in a 
hermetically sealed aluminum pans. Heat runs for each 
sample were set from 25 to 5000C at a heating rate of 
100C/min.15,16,17 
In-Vitro Drug Release Study: 
The in-vitro drug release experiment was developed to 
measure the drug release kinetics from the polymeric 
nanoparticle in a sink condition. Drug release study of 
capsules filled with nanoparticles was carried out using the 
USP II dissolution test apparatus (Veego VDA-8DR) under 
conditions at 37±0.50C and stirred at 100 rpm. The 
nanoparticle formulations are tested for drugs releases for 
8 hours in the dissolution medium with 0.1 N HCl+3% SLS 
solution. At each predetermined time intervals 5 ml of 
sample was taken and filtered by using by using Whatman 
filter paper No.41. After the appropriate dilutions the 
sample analyzed spectrophotometrically.18,19 
Stability study: 
Stability studies were carried out for the optimized batch 
having high entrapment efficiency and low particle size by 
storing (Remi SC-6 plus) the formulation at three different 
temperature conditions 4±20C, 25±20C and 40±20C. The 
drug content was estimated after every 15, 30 and 45 days 
as per ICH guidelines to find any change in the entrapment 
efficiency and particle size of the SLNs.20 
RESULTS AND DISCUSSION: 
Lyophilization: 
For improving physical and chemical stability 
lyophilization has been mostly used. But, this process may 
destroy the surfactant film around the nanoparticle due to 
a “freeze out” effect, and lead to particle aggregation 
during the resolublization or redispersion process, the 
sufficient protective effect can be provided. Mean particle 
size increased significantly after lyophilization without any 
cryoprotectant. Sorbitol, mannitol, maltos and dextran are 
examples of cryoprotectants. It will help to prevent the 
nanoparticle from aggregation. Mannitol works by forming 
film around surface of the nanoparticles, so there is no 
significant change in particle size after lyophilazation. 
FTIR Analysis: 
FTIR Spectroscopy was used to investigate the interaction 
between lipid, drug and Excipients. From the FTIR graphs 
of pure drug and optimized formulation (C), it is confirmed 
that there are no any interaction between the lipids and 
drug. FTIR Spectra of pure drug (a) and formulation (b) are 
shown in the figure 1. The FTIR chart obtained for pure 
Prazosin Hydrochloride bands at the region 3150-3050 cm-
1 the broad intense band for C-H stretching, primary 
amines and primary amides is at 3100-3500 cm-1. Other 
peaks are at 3302 cm-1 represents N-H Stretching, 1300-
1000 cm-1 the intense bands for C-O stretching shows 
carboxylic group at 1280 cm-1. 
 
 
Figure 1: FTIR Spectrum of Pure Prazosin Hydrochloride (A) and Optimized Batch (B) 
 
Evaluation of Prazosin Hydrochloride loaded Solid Lipid Nanoparticles: 
Practical yield:  
The percentage practical yield was observed ranges between 82±1.15 to 95.38±0.77. The percentage practical yield was 
observed to increase with the concentration of lipid (Table 2).  
Table 2: % Practical yield and % entrapment efficiency of nanoparticles (batch A-H) 
Formulation Code %Practical Yield %Entrapment Efficiency 
A 90.00±1.30 86.00±0.70 
B 89.39±1.52 83.42±0.90 
C 95.38±0.77 89.29±0.65 
D 85.83±1.66 81.71±1.29 
E 92.93±1.00 77.00±1.02 
F 90.97±1.79 72.57±1.12 
G 82.00±1.15 65.14±1.04 
H 85.24±1.01 66.28±0.84 
Each value is average of three separate determination ±SD 
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Entrapment efficiency: 
The percent entrapment was observed to vary within range 
65.14±1.04 to 89.29±0.65%. The percentage entrapment 
efficiency was observed to enhance with the increases in 
lipid concentration (batch A-C). Prazosin Hydrochloride 
loaded SLNs of batch C showed higher percent entrapment 
efficiency i.e 89.29±0.65% compared to other formulations 
(Table 2). 
Particle Size and Zeta Potential of Prepared SLNs of 
Prazosin Hydrochloride: 
Particle size and Zeta potential of the all batches of 
Prazosin Hydrochloride SLNs was measured. The particle 
size was observed in the range of 263.8±1.88 to 369.3±1 
nm with zeta potential 7.5±0.32 to -22.1±1.00 mV for the 
prepared batches of SLN. It has been observed that an 
increase in lipid content (GMS) does not significantly affect 
the particle size. The particle size and zeta potential are 
depicted in Table 3. 
The particle size distribution has a direct influence on 
material properties and found to be uniform (Figure 2). 
Determination of mean average particle size of Prazosin 
Hydrochloride solid lipid Nanoparticles was carried out by 
using Horiba instrument. Average particle size of all SLN 
preparations was found to be within range of 263.8±2 to 
295.3± 1.15. Determination of Zeta potential of prepared 
SLNs (Table 3) was found in the range of 7.5±0.32 to -
22.1±1 shown in the Figure 3. It was found that higher the 
zeta potential, less will be the particle aggregation, due to 
electric repulsion and hence more will be the stability of 
SLNs. 
Table 3: Mean particle size or average zeta potential of 
prazosin hydrochloride SLNs 
Formulation Code 
Size  
(nm) 
Average Zeta 
Potential (mV) 
A 283.5±2.0 7.5±0.32 
B 282.02±1.60 13.4±0.2 
C 263.8±1.88 -22.1±1.00 
D 295.3±1.55 8.7±0.41 
E 299.4±0.90 9.2±0.15 
F 304.6±1.52 10.3±0.30 
G 348.9±1.91 13.4±0.15 
H 369.3±1 17.7±0.87 
Each value is average of three separate determination ±SD 
  
 
Figure 2: Size Distribution Report of Optimized Batch 
 
 
Figure 3: Zeta Potential Report of Optimized Batch 
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Scanning Electron Microscopy Analysis: 
Scanning electron microscopy (SEM) is an electron optical 
imaging technique that provides photographic images and 
elemental information. The signals that derive from 
electron sample interaction reveal information about the 
sample including external morphology (texture), 
crystalline structure, and orientation of materials making 
up the sample. The Prazosin Hydrochloride appeared as 
smooth surfaced, irregularly flat shaped and crystalline in 
nature (Figure 4). SLNs were observed to be small sized, 
spherical in shape and porous in nature (Figure 5).   
 
Figure 4: Scaaning Electron Microscopy of Pure 
Prazosin Hydrochloride 
 
Figure 5: Scanning Electron Microscopy of Optimized 
Batch 
X-ray diffraction study: 
The XRD study of Solid Lipid Nanoparticle showed in 
Figure 6. Pure Prazosin Hydrochloride powder showed 
prominent diffraction peaks in the range of 1-40 of 2θ. But, 
no obvious peaks representing crystalline nature of 
Prazosin Hydrochloride was seen for the SLN, indicating 
the conversion to amorphous nature of Prazosin 
Hydrochloride in the formulation. It revealed that quite 
amorphization has occurred during SLNs preparation of 
Prazosin Hydrochloride. 
 
 
Figure 6:  X-RAY Diffraction Pattern of Pure Prazosin Hydrochloride (A) and Optimized Batch (B) 
 
 
Differential Scanning Calorimetry: 
Thermogram of Solid lipid Nanoparticle has been depicted 
in Figure 7. In the case of pure Prazosin Hydrochloride a 
sharp endothermic peak was observed at 283.310C, 
corresponding to its melting point. In the SLNs, endotherm 
was observed at near about 79.070C with the sharp 
appearance. It reveals that is no polymeric transition 
during Nanoparticles preparation of Prazosin 
Hydrochloride. 
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Figure 7: DSC Thermogram of Pure Drug Prazosin Hydrochloride (A) and Optimized Batch (B) 
 
In-Vitro release studies: 
In vitro drug release study of the all SLNs (A-H) was carried 
out depicted in Figure 8. The SLNs exhibited biphasic 
release pattern with initial release in 2 hours by sing 0.1N 
HCl + 3% SLS followed by sustained release for 8 hours. 
About 25-28% of incorporated amount of drugs was found 
to be released during first 2 hours, followed by a slowed 
release profile of the drug up to 8 hours (Table 4). The 
prolonged release at 8 hours can be attributed to slow 
diffusion of drug from lipid matrix.  
 
Table 4: percentage drug release of SLNs of batch A-H 
Formulation code % Drug Release at 8 hr 
A 95.16±1.590 
B 95.35±1.130 
C 97.35±0.790 
D 90.00±0.009 
E 95.46±0.019 
F 93.94±0.017 
G 92.88±0.010 
H 89.77±0.010 
Each value is average of three separate determination ±SD
 
 
Figure 8: Drug Release Profile of Nanoparticles Batches (A-H) 
 
Stability study: 
Stability studies were carried out for the optimized batch 
having high entrapment efficiency and low particle size by 
storing the formulation at three different temperature 
conditions as 40C, 25±20C and 40±20C. The drug content 
was estimated after every 15, 30 and 45 days as per ICH 
guidelines to find any change in the entrapment efficiency 
and particle size of the SLNs. The result was shown in the 
Table 5. SLNs were found to be stable over the above 
mentioned period as per ICH guidelines. 
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Table 5: stability study for solid lipid nanoparticles of prazosin hydrochloride (batch-C) 
Storage 
Condition 
Particle Size (nm) Entrapment Efficiency (%) 
Initial 15 days 30 days 45 days Initial 15 days 30 days 45 days 
40C 263.8±1.88 263.80±0.54 262.13±0.01 257.81±0.56 89.29±0.65 88.47±0.59 87.4±0.60 87.1±1.00 
250C 263.8±1.88 261.00±0.81 259.14±0.04 256.46±0.61 89.29±0.65 88.36±0.38 87.1±0.04 85.1±0.01 
400C 263.8±1.88 261.39±1.09 260.15±0.02 256.17±0.02 89.29±0.65 88.10±0.25 86.1±0.03 84.2±0.15 
 
CONCLUSION 
Hot homogenization followed by solvent emulsification-
ultrasonication method was a useful method for the 
successful incorporation of the poor water soluble drug 
Prazosin Hydrochloride with good entrapment efficiency. 
The Preformulation study showed the compatibility of 
Prazosin Hydrochloride with the other formulation 
ingredients and the drug is molecularly dispersed into the 
lipid. The particle size distribution shows the particle size 
in the nano range. In-vitro drug release through the dialysis 
membrane from the prepared SLNs is much higher than 
the pure drug. The Stability study showed that 
formulations did not changed their performance on 
storage. Hence formulation of Prazosin Hydrochloride in 
SLNs can enhance the bioavailability of the drug which 
could be stabilized during storage. 
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